Uterine leiomyoma, a benign smooth-muscle tumor of the myometrium, is the most commonly encountered neoplasm in women of reproductive age. Band q15 of chromosome 12 is often rearranged in benign mesenchymal tumors such as uterine leiomyomas, and the HMGIC gene, encoding a protein of the high-mobility-group (HMG), is present in that region. Using 3′ ′ ′ ′ rapid amplification of cDNA ends (3′ ′ ′ ′RACE) experiments, we isolated an ectopic sequence that was fused to HMGIC in a uterine leiomyoma. Cloning of the fusion cDNA identified a gene termed "homo sapiens enhancer of invasion 10" (HEI10) as the fusion partner. Radiation hybrid mapping revealed that the normal location of HEI10 is at 14q11. In the fusion transcript the first two exons of the HMGIC gene, which encode DNA-binding domains, were fused to the 3′ ′ ′ ′ portion of the HEI10 gene. This rearrangement implicates HMGIC in the tumorigenesis of uterine leiomyoma, and suggests that its fusion HMGIC product may play a role in mesenchymal differentiation.
Uterine leiomyoma is the most commonly encountered benign muscle tumor in women of reproductive age, 1) but its pathogenesis remains unresolved although cytogenetic studies have described several tumor-specific chromosomal aberrations in benign tumors including leiomyomas.
One of these, chromosomal translocation t(12:14) (q13-15:q23-24), is typically associated with benign tumors; this aberration sometimes includes rearrangement of HMGIC, a gene of the high-mobility-group (HMG) family, that may involve novel fusions. 2, 3) HMG proteins are nonhistone nuclear proteins that play an important role in the regulation of chromatin structure and function. HMGIC and HMGI(Y) are members of the HMGI family of HMG proteins. HMGIC and HMGI(Y) dysregulation as a result of specific rearrangements involving 12q15 4) and 6q21, 5) the respective chromosomal sites in which the HMGIC and HMGI(Y) genes are located, is also found in a variety of common benign mesenchymal tumors. The HMGIC gene consists of five exons, encoding three DNAbinding domains, one spacer domain, and one acidic regulatory domain. We would expect a rearrangement and/or disruption of HMGIC to be a critical factor in cellular proliferation and thus in development of neoplasms.
Until now, only a few genes, e.g. ALDH2, 6) RAD51B, 7) and COX6C 8) were known to be fused with HMGIC in uterine leiomyomas, but we suspected that other genes might also have this property. Using 3′ rapid amplification of cDNA ends (3′RACE) and reverse transcriptase-polymerase chain reactions (RT-PCRs), we screened 16 uterine leiomyomas and identified a novel fusion partner of HMGIC in one of those tumors.
MATERIALS AND METHODS
Tumor samples and extraction of RNA and DNA Uterine leiomyomas were obtained from 16 patients at the time of surgery in the Nippon Medical School Hospital, frozen immediately, and stored at −70°C until extraction. From approximately 100 mg of each leiomyoma tissue, total RNA was extracted by the guanidine thiocyanate method, 9) using an Isogen RNA extraction kit (Nippon Gene, Tokyo). DNA was isolated by procedures described previously. 10) PCR primers and hybridization probe The sequences of the oligonucleotide primers (AP1, AP2, H1-H5, C1-C3) and the hybridization probe (A) are listed in Table I . 3′ ′ ′ ′ rapid amplification of cDNA ends (3′ ′ ′ ′RACE) To screen for fusions involving HMGIC, we reverse-transcribed 5 µg of total RNA from each of the 16 tumors with Superscript II (Life Technologies, Rockville, MD) for 50 min at 42°C in a 40-µl reaction mixture containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol (DTT), 0.5 mM dNTP and 50 pmol of adapter primer 1 (AP1). The RNA was then digested with 6 U of RNaseH (TaKaRa, Tokyo) at 37°C for 30 min. For the first, second and third rounds of PCR we used the adapter primer 2 (AP2) as reverse primer. As forward primers we used the HMGIC-specific sequence H1 (HMGIC exon 1) in the first round, nested primer H2 (HMGIC exons 1 and 2) in the second round, and nested primer H3 (HMGIC exon 2) in the third round. Firststrand cDNA was used as the template for the first PCR in a total volume of 10-µl containing 1× KlenTaq PCR reaction buffer (Clontech, Palo Alto, CA), 0.2 mM of each dNTP, 4 pmol of each primer, and 1× Advantage KlenTaq Polymerase Mix (Clontech). Cycle conditions were 94°C for 2 min, then 30 cycles of 90°C for 10 s, 60°C for 30 s, and 68°C for 4 min, in a Gene Amp PCR 9600 System (Perkin Elmer Cetus, Foster City, CA). In the second and third rounds, a 1/50 portion of the first-round PCR product was used as the template. Nested PCR conditions were as described above except that amplification proceeded for 25 cycles. Hybridization of oligonucleotide probe The nested PCR products from the 3′RACE experiments were electrophoresed on 3% NuSieve agarose gels (FMC, Rockland, ME) and transferred to nylon membranes. A gene-specific oligonucleotide probe (A) from exon 2 of HMGIC was end-labeled with [γ-32 P]ATP by T4 polynucleotide kinase. This probe was hybridized to the blotted membranes according to procedures described previously.
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Cloning and sequencing of a fusion transcript 3′RACE products that were positive for hybridization were subcloned into the plasmid vector pBlueScript II (SK+) and sequenced on a 377 DNA sequencer (Applied Biosystems, Weiterstadt, Germany). Radiation-hybrid mapping Radiation-hybrid (RH) mapping was performed with the Stanford G3 RH panel available from Research Genetics. DNA from each RH clone was amplified with primers specific to the fused sequence, HEI10. PCR products were electrophoresed on 3% agarose gels (3:1 NuSieve: Seakem; FMC) and visualized with ethidium bromide. The gels were scored for the presence of amplified products, and the results were submitted to the World Wide Web server of the Stanford Human Genome Center (http://www-shgc.stanford.edu). RT-PCR RT-PCRs were performed to detect expression of chimeric HMGIC/HEI10 mRNA. Each PCR was carried out with a sense primer specific for HMGIC sequence and an anti-sense primer specific for HEI10 sequence, with the primer pairs chosen to flank the breakpoints. The PCR conditions were as described previously.
12)

RESULTS
To identify transcripts representing possible fusions between HMGIC and ectopic sequences we screened RNAs from 16 uterine leiomyomas by 3′RACE experiments, using HMGIC cDNA sequences as primers. In one tumor (#47), hybridization of a 3′RACE product to HMGIC probe A revealed an aberrant band of 873 bp in myoma #47, but, no signal at 3211 bp that would be expected from the native structure of HMGIC gene was detected in the lane where the 3′RACE product of normal uterine tissue was loaded (Fig. 1A) . This is in accord with the fact that HMGIC gene is transcribed only in fetal tissue but not in any adult tissue. When this aberrant band from myoma #47 was extracted from the gel, cloned, and sequenced we detected an ectopic sequence downstream of HMGIC exon 2, indicating that this rearrangement had occurred within intron 2 of the HMGIC gene.
The fused sequence was mapped by means of the G3 RH mapping panel of 83 hybrid cell lines from the Stanford Human Genome Center (http://www-shgc.stanford. Fig. 1 . A. Autoradiogram from a 3′RACE experiment whose product hybridized to the HMGIC-specific probe. 3′RACE was performed using primers H1-H3, AP1 and AP2. PCR products were separated on 3% NuSieve agarose gels and transferred to nylon membranes. The gene-specific oligonucleotide probe (A) was hybridized to the blotted membranes. B. Positions and orientation (arrows) of oligonucleotide primers H1-H3, AP1, and AP2 for 3′RACE analysis. The location of probe A is indicated with a short horizontal bar. DBD, DNA-binding domain; UTR, untranslated region.
edu), through linkage to markers that had been cytogenetically mapped to 14q11. Thus parts of the HMGIC gene at 12q15 and the gene at 14q11 were juxtaposed in tumor 47, the most likely mechanism of this event being a chromosomal translocation between 12q15 and 14p11. The breakpoint of each chromosomal band would have occurred within the two genes in question.
A search for homologies with the BLAST program revealed that the novel fusion sequence was identical to a human sequence that had been submitted directly to Genbank under the name "Homo sapiens enhancer of invasion 10" (HEI10) mRNA (Fig. 2) . Analysis of the aberrant transcript revealed that the first two exons of the HMGIC gene, which encode DNA-binding domains, were fused to the 3′ portion of the HEI10 sequence. Fig. 3 shows sequences surrounding the breakpoint between the two genes. The fusion product consists of the N-terminal 66 amino acids of HMGIC protein and the 178 C-terminal residues of HEI10 protein.
To confirm that HMGIC-HEI10 fusion mRNA was indeed produced in this tumor, we performed RT-PCR experiments with three HEI10-specific primers (C1, C2, and C3) and HMGIC-specific primer H2. As expected, HMGIC-HEI10 fusion products of 330, 378 and 694 bp were amplified, respectively, by primer pairs H2-C1, H2-C2 and H2-C3 when RNA from this tumor was used as the template, but not when the RNA was from normal myometrium of the same patient (Fig. 3A) .
DISCUSSION
Translocations involving chromosomes 12 and 14, especially region 12q13-15, are observed in a variety of benign tumors, including lipomas, pleiomorphic adenomas, and uterine leiomyomas. Rearrangements of HMGIC, a gene located on 12q13-14, are often associated with these chromosomal translocations, and fusion with other genes is a typical feature of these events. Since HMGIC protein binds to the minor groove of AT-rich DNA 13) and modifies DNA binding/conformation, we believe that HMGIC acts as an architectural transcriptional complex. 14, 15) There has been no report of translocation or gene-fusion involving HEI10 located at 14q11 in any tumor. This chromosomal location is far centromeric from the breakpoint, 14q23-24, observed in some uterine myomas.
Using 3′RACE to analyze 16 primary uterine leiomyomas, we identified a sequence termed HEI10 as a novel fusion partner of HMGIC in one of the tumors. Its mRNA sequence, which had been submitted directly to Genbank by others, was the sole information available for HEI10 before we mapped it to chromosome 14. Although we have no clues to the functional significance of the fusion event between HMGIC and HEI10 in tumor 47 with regard to cellular proliferation, we speculate that the rearrangement involving HEI10 that occurred within DNAbinding domains of the HMGIC gene would disrupt the normal structure of the HMGIC product and might confer its DNA-binding capacity on the novel fusion product. Recently a rearrangement of HMGIC in a pleomorphic adenoma of the parotid gland was reported in the 3′UTR of HMGIC, leaving the complete coding region intact but removing eight AUUUA motifs. 16) That motif has been linked to rapid deadenylation and subsequent decay of mRNAs. 17) A transcript lacking this motif could yield a more stable HMGIC mRNA, which might affect levels of HMGIC protein in the cells and ultimately, control of cell proliferation. Therefore, it may well be that separation of the DNA binding domains of HMGIC from its 3′UTR sequence, especially the eight AUUUA motifs, is the key mechanism of a variety of HMGIC-related gene fusion events that may contribute to development of uterine leiomyomas and other benign neoplasms.
Several previous studies have emphasized the importance of derangement of the native HMGIC gene structure itself, rather than acquisition of new function(s), when gene-fusion events occur. [16] [17] [18] [19] [20] We recently suggested that the contribution of partner genes to the pathogenesis of uterine leiomyomas was likely to be limited because the C-terminal part derived from one partner gene, COX6C, encoded only a few amino acids. 8) The results of the present study are consistent with that proposition.
